This case report by Teixeira et al. details an adult female with recalcitrant #PityriasisRubraPilaris (PRP), initially treated with #ustekinumab. After #disease progression, transitioning to #guselkumab led to a remarkable #clinical response. 👉 bit.ly/3X60AQv

FDA approves #Guselkumab (Tremfya) for ulcerative colitis. New hope for patients with moderate-to-severe #UC, showing clinical remission in QUASAR trials. bit.ly/3TqQvvn #IBD #UlcerativeColitis

#ECA #GUIDE 👉NO inferioridad de la dosificación de #Guselkumab durante 1⃣6⃣ semanas VS de 8⃣semanas en pacientes con respuesta superior en pacientes con #psoriasis vía JAMA Dermatology jamanetwork.com/journals/jamad…

A meaningful impact on individual and overall signs, symptoms, and #QOL continued for some patients with #plaquepsoriasis who were treated with #guselkumab and maintained complete skin clearance for 3 years or longer. #psoriasis ⬇️ dermatologyadvisor.com/news/psoriasis…

From the September issue: Battle Royale! Who comes out on top: #guselkumab or #adalimumab? ow.ly/EEqp50SjTSp #dermtwitter #medderm

🧵 FDA Approves TREMFYA (Guselkumab) for Moderately to Severely Active Ulcerative Colitis #Tremfya #Guselkumab #FdaApproval #UlcerativeColitis #InflammatoryBowelDisease #JohnsonJohnson

FDA approves #guselkumab for ulcerative colitis. QUASAR trials reveal major improvements in clinical remission for #UC patients with limited treatment options. bit.ly/3TqQvvn

Buenas noticias: la U.S. FDA da vía libre al #guselkumab en las #EII completando el elenco de #antiIL23 en la #IBD

#Guselkumab demonstrated durable improvements in quality of life, with 72% of patients achieving a DLQI score of 0/1 at Week 56 in the POLARIS trial. ow.ly/uoVX50SVzL2

ICYMI: In randomized controlled trials, #guselkumab had favorable efficacy and safety profiles for up to 5 years in #psoriasis and up to 2 years in psoriatic #arthritis. #AADReadingRoom AAD #dermatology Read more: shorturl.at/QTTKe

Patients treated with #guselkumab in the #POLARIS trial had a lower rate of adverse events and discontinuations compared to those treated with FAE, supporting its favourable safety profile ow.ly/bb9G50SVzGV

In the #POLARIS study, #guselkumab maintained higher PASI90 response rates at Week 56 in fumaric acid esters (FAE) non-responders who switched to guselkumab, with 80% achieving PASI90 ow.ly/UHyF50SVzxy

PPACMAN Board Members Joseph F. Merola, MD MMSc and Drs. AlexisO, Christopher Ritchlin, and Philip Mease co-authored an article on the efficacy and safety of #guselkumab, used for the treatment of plaque #psoriasis. Full article: bmcrheumatol.biomedcentral.com/articles/10.11… #DermTwitter #PsA #Dermatology

Interested in long-term #PsA management? Ritchlin et al.'s post hoc analysis showed sustained efficacy of #guselkumab over 2 years, across various domains and #patient characteristics. Improve your understanding with the #IMIDForum today! ow.ly/oNcB50SFV6L

Ritchlin et al. observed that #guselkumab treatment led to improvements in both physical function and quality of life for #PsA patients. Discover the complete study with our detailed slide summary over on the #IMIDForum ow.ly/bcgl50SFV0k

Our #PsA podcast this month sees world experts discuss the association between genetic markers and their response to #biologics, as well as a post hoc analysis across domains and patient characteristics with #guselkumab – listen for free! 🔗ow.ly/alWG50SJUyz

Ritchlin et al. reported that #guselkumab displays robust efficacy in managing #PsA across various domains. Read the full details of this Phase 3 post hoc analysis and enhance your understanding on the #IMIDForum today, for free! ow.ly/By8k50SFUVC